Lebrikizumab provides clinically meaningful responses in adults with moderate-to-severe atopic dermatitis in two phase 3 monotherapy studies

This Medfyle was published more than two years ago. More recent Medfyle on this topic may now be available.

Key messages

• Lebrikizumab is a novel, high-affinity monoclonal antibody targeting IL-13 under development for moderate-to-severe AD.
• ADvocate-1 and -2 randomised dupilumab- and tralokinumab-naïve adults and adolescents to lebrikizumab 250 or 500 mg, or placebo Q2W.
• This post hoc analysis reported the proportion of adults achieved one or more of three key responses: EASI <7, PNRS ≥4, and DLQI ≤5.
• At Week 16, 74.6% and 35.1% of lebrikizumab and placebo patients achieved ≥1 clinically meaningful response in signs, symptoms, or QoL.
• All three endpoints were achieved by 36.6%/22.7% of patients on lebrikizumab, versus 6.3%/5.3% on placebo in the ADvocate-1/-2 trials.